Literature DB >> 12032329

Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.

Kulkarni Prakash1, Gregorio Pirozzi, Michael Elashoff, William Munger, Iwao Waga, Rajiv Dhir, Yoshiyuki Kakehi, Robert H Getzenberg.   

Abstract

Benign prostatic hyperplasia (BPH) is a disease of unknown etiology that significantly affects the quality of life in aging men. Histologic BPH may present itself either as symptomatic or asymptomatic in nature. To elucidate the molecular differences underlying BPH, gene expression profiles from the prostate transition zone tissue have been analyzed by using microarrays. A set of 511 differentially expressed genes distinguished symptomatic and asymptomatic BPH. This genetic signature separates BPH from normal tissue but does not seem to change with age. These data could provide novel approaches for alleviating symptoms and hyperplasia in BPH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032329      PMCID: PMC124296          DOI: 10.1073/pnas.112191399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Growth factors and epithelial-stromal interactions in prostate cancer development.

Authors:  Y C Wong; Y Z Wang
Journal:  Int Rev Cytol       Date:  2000

Review 2.  Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members.

Authors:  F Nollet; P Kools; F van Roy
Journal:  J Mol Biol       Date:  2000-06-09       Impact factor: 5.469

3.  Differential expression of osteonectin/SPARC during human prostate cancer progression.

Authors:  R Thomas; L D True; J A Bassuk; P H Lange; R L Vessella
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

Review 4.  Benign prostatic hyperplasia (the aging prostate).

Authors:  J J Medina; R O Parra; R G Moore
Journal:  Med Clin North Am       Date:  1999-09       Impact factor: 5.456

5.  Asymptomatic inflammation and/or infection in benign prostatic hyperplasia.

Authors:  J C Nickel; J Downey; I Young; S Boag
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

6.  Immune response in hormonally-induced prostatic hyperplasia in the dog.

Authors:  W Mahapokai; T S van den Ingh; F van Mil; E van Garderen; J A Schalken; J A Mol; F J van Sluijs
Journal:  Vet Immunol Immunopathol       Date:  2001-02-10       Impact factor: 2.046

Review 7.  Benign prostatic hyperplasia: challenges for the new millennium.

Authors:  M A Cabelin; A E Te; S A Kaplan
Journal:  Curr Opin Urol       Date:  2000-07       Impact factor: 2.309

8.  Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.

Authors:  U Elsässer-Beile; B Przytulski; D Gierschner; T Grussenmeyer; A Katzenwadel; C Leiber; A Deckart; U Wetterauer
Journal:  Prostate       Date:  2000-09-15       Impact factor: 4.104

Review 9.  [Drugs for the treatment of benign prostatic hypertrophy].

Authors:  L Caprino
Journal:  Minerva Urol Nefrol       Date:  2000-06       Impact factor: 3.720

10.  Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray.

Authors:  J H Bull; G Ellison; A Patel; G Muir; M Walker; M Underwood; F Khan; L Paskins
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

View more
  47 in total

1.  Extracellular matrix associated protein CYR61 is linked to prostate cancer development.

Authors:  Katherine B D'Antonio; Antoun Toubaji; Roula Albadine; Alison M Mondul; Elizabeth A Platz; George J Netto; Robert H Getzenberg
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

Review 2.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

3.  Developmental, cellular and molecular biology of benign prostatic hyperplasia.

Authors:  William A Ricke; Jill A Macoska; Gerald R Cunha
Journal:  Differentiation       Date:  2011-08-30       Impact factor: 3.880

Review 4.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

5.  A signaling network in phenylephrine-induced benign prostatic hyperplasia.

Authors:  Jayoung Kim; Yutaka Yanagihara; Tadahiko Kikugawa; Mihee Ji; Nozomu Tanji; Yokoyama Masayoshi; Michael R Freeman
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

Review 6.  A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Authors:  Chris Mullins; M Scott Lucia; Simon W Hayward; Jeannette Y Lee; Jonathan M Levitt; Victor K Lin; Brian C-S Liu; Arul M Chinnaiyan; Mark A Rubin; Kevin Slawin; Robert A Star; Robert H Getzenberg
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

Review 7.  Biomarkers for benign prostatic hyperplasia progression.

Authors:  Grant W Cannon; Robert H Getzenberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 8.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

9.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07

10.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.